Press Release November 21, 2022

Merck To Acquire Imago BioSciences, Inc. for $1.35 Billion

The M&A and Life Sciences teams advised Centerview Partners in its role as the financial advisor to Imago BioSciences, Inc. (Nasdaq: IMGO) in a definitive agreement for Merck (NYSE: MRK), through a subsidiary, to acquire Imago for $36.00 per share in cash, for an approximate total equity transaction value of $1.35 billion.

Centerview Partners is a leading independent investment banking and advisory firm. The firm provides advice on mergers and acquisitions, financial restructurings, valuation, and capital structure to companies, institutions and governments. Since the founding of Centerview in 2006, the firm has advised on nearly $3 trillion of transactions.

Imago is a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases. Imago’s lead candidate bomedemstat (IMG-7289), an investigational orally available lysine-specific demethylase 1 (LSD1) inhibitor, is currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia (ET), myelofibrosis (MF), and polycythemia vera (PV), in addition to other indications.

The Goodwin team was led by Stuart Cable, Jim Matarese, and Blake Liggio.

For more details, read the press release.